STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
The recent success of a late-stage mRNA cancer vaccine, showing the drug stopped the return of melanoma, has boosted hopes that the approach can be successfully harnessed to attack other cancers. The question now is which ones — and whether mRNA is…
ImpactNotable 47/100
Why it mattersRule-based estimate: event keywords (+18); trust 8/10.
RegionsGlobal
Published2 h ago (Mon, 05 Oct 2026 08:30:00 GMT)
RetrievedMon, 05 Oct 2026 09:00:14 GMT via rss
ClassifiedMon, 05 Oct 2026 09:00:21 GMT by heuristic
AuthorAllison DeAngelis